VERVE-101

N/A

Report date: 2025/08/11 17:53:13

Base Information

Drug NameVERVE-101
Drug Alias NameVERVE-101
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionGene silencingProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaAtherosclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBroad InstituteHarvard University
China Registration ClassN/A

Develop Information

Active CompaniesVerve Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaAtherosclerosis
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A